[HTML][HTML] Immunotherapy in head and neck cancer: aiming at EXTREME precision
P Szturz, JB Vermorken - BMC medicine, 2017 - Springer
Background Locoregionally advanced, recurrent, and metastatic squamous cell carcinomas
of the head and neck (SCCHN) remain difficult to treat disease entities, in which systemic …
of the head and neck (SCCHN) remain difficult to treat disease entities, in which systemic …
Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN).
BS Glisson, J Tseng, S Marur, DM Shin, BA Murphy… - 2013 - ascopubs.org
6030 Background: Preclinical evidence supports clinical investigation of IGF-1R inhibitors
alone, or combined with EGFR inhibitors, in SCCHN patients (pts). CIX and CET monoclonal …
alone, or combined with EGFR inhibitors, in SCCHN patients (pts). CIX and CET monoclonal …
[HTML][HTML] Real-world use of first-line pembrolizumab+ platinum+ taxane combination regimens in recurrent/metastatic head and neck squamous cell carcinoma
Introduction The programmed death-1 (PD-1) immune checkpoint inhibitor pembrolizumab
is currently approved in the US for the first-line (1L) treatment of recurrent or metastatic head …
is currently approved in the US for the first-line (1L) treatment of recurrent or metastatic head …
[HTML][HTML] Nivolumab vs investigator's choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect …
L Licitra, RL Ferris, G Blumenschein… - Annals of …, 2017 - annalsofoncology.org
Background: In CheckMate 141, nivolumab monotherapy significantly prolonged overall
survival (OS) vs IC (median [95% CI]: 7.5 [5.5, 9.1] mo vs 5.1 [4.0, 6.0] mo) and doubled …
survival (OS) vs IC (median [95% CI]: 7.5 [5.5, 9.1] mo vs 5.1 [4.0, 6.0] mo) and doubled …
[HTML][HTML] Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from …
Objectives To assess health-related quality of life (HRQoL) with first-line pembrolizumab,
pembrolizumab-chemotherapy, or cetuximab-chemotherapy in recurrent or metastatic head …
pembrolizumab-chemotherapy, or cetuximab-chemotherapy in recurrent or metastatic head …
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck …
B Burtness, KJ Harrington, R Greil, D Soulières… - The Lancet, 2019 - thelancet.com
Background Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC),
with programmed cell death ligand 1 (PD-L1) expression associated with improved …
with programmed cell death ligand 1 (PD-L1) expression associated with improved …
Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a …
J Trigo, R Hitt, P Koralewski, E Diaz-Rubio… - Journal of Clinical …, 2004 - ascopubs.org
5502 Background: Pts with refractory SCCHN have a poor prognosis with few therapeutic
options. Cetuximab (Erbitux), an IgG1 monoclonal antibody that binds selectively to EGFR …
options. Cetuximab (Erbitux), an IgG1 monoclonal antibody that binds selectively to EGFR …
[HTML][HTML] A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic …
P Bossi, R Miceli, LD Locati, D Ferrari, S Vecchio… - Annals of …, 2017 - Elsevier
Abstract Background B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b,
noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin …
noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin …
[HTML][HTML] Treatment sequences in patients with recurrent or metastatic head and neck squamous cell carcinoma: cetuximab followed by immunotherapy or vice versa
CC Yang, CF Lien, TZ Hwang, CC Wang, CC Wang… - Cancers, 2022 - mdpi.com
Simple Summary As the treatment advances, there were several novel agents developed for
R/M HNSCC, including an anti-epidermal growth factor receptor antibody, cetuximab, and …
R/M HNSCC, including an anti-epidermal growth factor receptor antibody, cetuximab, and …
Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck …
N Takeshita, T Enokida, S Okano, T Fujisawa, A Wada… - Oral Oncology, 2023 - Elsevier
Objectives Cetuximab-based chemotherapy is a standard 1st-line treatment for recurrent
and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However …
and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However …